SCM Lifescience

BG Rhee, Ph.D., CEO
Incheon, Korea
(KOSDAQ: 298060)
SCM Lifescience is a clinical-stage biopharmaceutical company specializing in the development of innovative stem cell and immune cell therapeutics. The company is using its proprietary subfractionation culturing method to isolate homogeneous population of clonal mesenchymal stem cells, serving as basis to its stem cell pipelines: SCM-CGH for treatment of chronic graft-versus-host disease, and SCM-AGH for treatment of atopic dermatitis and acute pancreatitis. It has recently expanded into the immuno-oncology sector through its U.S.-based subsidiary, CoImmune, incorporating allogeneic, non-viral use CAR-CIK, and dendritic cell cancer vaccine into its development. With strong capabilities around cell therapy research and development and the US-based cGMP manufacturing facility, SCM Lifescience is focused on accelerating product candidates through clinical trials to provide benefits to patients in high unmet medical need.
www.scmlifescience.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions